Atrin’s technology and products are the result of years of work that began as a postdoctoral study by Dr. Oren Gilad with Professor Eric Brown at the University of Pennsylvania, School of Medicine. The question they sought to answer was: is ATR a good target for cancer therapy? Over the next four years, they investigated the ATR protein, as well as its biological function and mechanism of action.
Dr. Gilad and Dr. Brown were seeking to confirm that ATR inhibitors could become a powerful new way of treating cancers with unmet need.
Dr. Brown and Dr. Gilad’s results showed that ATR is hyperactive in cancer cells compared to normal cells, suggesting that ATR performs a vital function without which cancer cells could be destroyed. In 2010, they published their findings, concluding that a drug that would reduce ATR would be an effective treatment against certain cancers.
Atrin was then established in 2012 to develop best-in-class drugs inhibiting ATR, and efficiently destroy cancer cells. Atrin’s lead compound, ATRN-119, is expected to enter human clinical trials in early 2022.
ATRN-119 has demonstrated a clearly differentiated tolerability profile across multiple species (mouse, rat, dogs), with negligible anemia or neutropenia at human equivalent doses of 1 gram per day.
ATRN-119 appears to have potency, specificity and notable tolerability advantages over other clinical-stage ATRi. Atrin believes these notable advantages will make ATRN-119 the best-in-class ATR product in the long run.